In 455 patients with untreated metastatic colorectal cancer on chemotherapy plus bevacizumab, high-dose vs standard-dose vitamin D3 did not improve median progression-free survival (11.8 vs 10.3 months; P=.25); overall survival and response also did not differ.
RCTn = 455
Ng et al. Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703)